A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Clinical trial NCT07383506 · RECRUITING

Trial details

NCT number: NCT07383506
Sponsor: Cogent Biosciences, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

PIK3CA Mutations Advanced Solid Tumors, Adult Endometrial Cancer HR Positive/HER-2 Negative Breast Cancer HER2-low Breast Cancer

Start date: 2026-06-01
Primary completion: 2029-07-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.